During the past decade, Beyza Ünalan Değirmenci conducted 4 clinical trials. In the 10-year time frame, 4 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Beyza Ünalan Değirmenci" are "Candidiasis, Oral" (1 trials), "Color; Change Teeth, Posteruptive" (1 trials), "Extracorporeal Shock Wave Therapy" (1 trials), "Gingival Disease" (1 trials) and "Occlusion" (1 trials). Many other conditions were trialed in "Beyza Ünalan Değirmenci" in a lesser frequency.

Most popular intervention types in "Beyza Ünalan Değirmenci" are "Procedure" (2 trials), "Device" (1 trials), "Drug" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Chemical Bleaching" (1 trials), "Chlorhexidine gluconate disinfection and microwave application" (1 trials), "Chlorhexidine gluconate disinfection and ozone therapy" (1 trials), "Etodolac 400 MG" (1 trials) and "Extracorporeal Shock Wave Therapy" (1 trials). Other intervention names were less common.

The vast majority of trials in "Beyza Ünalan Değirmenci" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Beyza Ünalan Değirmenci". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Beyza Ünalan Değirmenci, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Beyza Ünalan Değirmenci, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 5 trials that are defined as “Not Applicable".